Idera Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 87   

Articles published

IDRA 2.51 +0.01 (0.40%)
price chart
Idera Pharmaceuticals Expands Pipeline by Initiating Clinical Development of ...
CAMBRIDGE, Mass., Oct. 14, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, today announced it has ...
Related articles »  
Why Idera Pharmaceuticals, Inc. Shares Slipped From a Huge Pop Today
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Idera Announces Agreement with Abbott to Develop a Companion Diagnostic for ...  MarketWatch
Related articles »  
Why Idera Pharmaceuticals, Inc. Shares Popped
What: Shares of Idera Pharmaceuticals (NASDAQ: IDRA ) , a clinical-stage biopharmaceutical company focused on developing DNA and RNA-based therapeutics for autoimmune diseases, advanced as much as 13% after announcing the publication of ...
Related articles »  
Why Idera Pharmaceuticals Inc. Shares Roared Higher
What: Shares of Idera Pharmaceuticals (NASDAQ: IDRA ) , a clinical-stage biotechnology company focused on discovering novel drugs to modify immune responses through toll-like receptors, jumped as much as 13% after reporting its first-quarter results ...
Related articles »  
Why Idera Pharmaceuticals Inc. Shares Jumped
What: Shares of Idera Pharmaceuticals (NASDAQ: IDRA ) , a clinical-stage biopharmaceutical company developing DNA- and RNA-based therapies, jumped by as much as 22% after announcing positive top-line data from its midstage study of IMO-8400 as a ...
Idera Pharmaceuticals Inc. Stock Downgraded (IDRA)  TheStreet.com
Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of ...  Business Wire (press release)
Related articles »  
Idera Pharmaceuticals to Present at the Stifel 2014 Healthcare Conference
13, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing novel nucleic acid therapeutics for rare diseases, today announced that Company management will present at the Stifel ...
Related articles »  
Idera Pharmaceuticals Inc (IDRA) news: Idera: A Compelling Biotech Pick For ...
In this article, I write about one of my �top picks� to consider for March; Idera Pharmaceuticals. This company is working to treat autoimmune diseases and certain genetically defined forms of B-cell lymphoma.
Idera Pharmaceuticals, Inc. Bouncing on Phase 2 Success
Idera Pharmaceuticals' (NASDAQ: IDRA ) stock market rollercoaster ride left it partially recovered from its 25% plunge just over a week ago upon FDA approval of a competing product developed by Celgene (NASDAQ: CELG ) .
Better Psoriasis Treatments Needed Worldwide, Panel Says  Guardian Liberty Voice
Related articles »  
Idera Pharmaceuticals Reports Third Quarter Financial Results and Announces ...
CAMBRIDGE, Mass., Nov. 7, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for rare diseases, today reported financial results and business ...
Related articles »  
Idera Pharmaceutical Up After Market; Big Moves in Agios and Idenix
Idera Pharmaceuticals Inc (IDRA) was up over 4.42% in after-hours trading yesterday after data was released that shows its Toll-like Receptor (TLR) antagonist, IMO-8400, is able to inhibit the spread and survival of B-cell lymphoma cells that carry the ...